Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline leading to dementia and death. AD imposes neuronal death by the intricate interplay of different neurochemical factors, which continue to inspire the medicinal chemist as molecular targets for the development of new agents for the treatment of AD with diverse mechanisms of action, but also depict a more complex AD scenario. Within the wide variety of reported molecules, this review summarizes and offers a global overview of recent advancements on naphthoquinone (NQ) and anthraquinone (AQ) derivatives whose more relevant chemical features and structure-activity relationship studies will be discussed with a view to providing the perspective for the design of viable drugs for the treatment of AD. In particular, cholinesterases (ChEs), β-amyloid (Aβ) and tau proteins have been identified as key targets of these classes of compounds, where the NQ or AQ scaffold may contribute to the biological effect against AD as main unit or significant substructure. The multitarget directed ligand (MTDL) strategy will be described, as a chance for these molecules to exhibit significant potential on the road to therapeutics for AD.
Alzheimer's disease (pan class="Disease">AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline leading to dementia and death. AD imposes neuronal death by the intricate interplay of different neurochemical factors, which continue to inspire the medicinal chemist as molecular targets for the development of new agents for the treatment of AD with diverse mechanisms of action, but also depict a more complex AD scenario. Within the wide variety of reported molecules, this review summarizes and offers a global overview of recent advancements on naphthoquinone (NQ) and anthraquinone (AQ) derivatives whose more relevant chemical features and structure-activity relationship studies will be discussed with a view to providing the perspective for the design of viable drugs for the treatment of AD. In particular, cholinesterases (ChEs), β-amyloid (Aβ) and tauproteins have been identified as key targets of these classes of compounds, where the NQ orAQ scaffold may contribute to the biological effect against AD as main unit or significant substructure. The multitarget directed ligand (MTDL) strategy will be described, as a chance for these molecules to exhibit significant potential on the road to therapeutics forAD.
Entities:
Keywords:
AChE and BChE inhibition; Alzheimer’s disease (AD); Aβ aggregation inhibition; Tau inhibition; multitarget directed ligands; naphthoquinone/anthraquinone derivatives
Authors: Quentin I Churches; Joanne Caine; Kate Cavanagh; Vidana Chandana Epa; Lynne Waddington; C Elisabet Tranberg; Adam G Meyer; Jose N Varghese; Victor Streltsov; Peter J Duggan Journal: Bioorg Med Chem Lett Date: 2014-05-13 Impact factor: 2.823
Authors: Vittorio Calabrese; Carolin Cornelius; Cesare Mancuso; Giovanni Pennisi; Stella Calafato; Francesco Bellia; Timothy E Bates; Anna Maria Giuffrida Stella; Tony Schapira; Albena T Dinkova Kostova; Enrico Rizzarelli Journal: Neurochem Res Date: 2008-07-16 Impact factor: 3.996
Authors: Gal Bitan; Marina D Kirkitadze; Aleksey Lomakin; Sabrina S Vollers; George B Benedek; David B Teplow Journal: Proc Natl Acad Sci U S A Date: 2002-12-27 Impact factor: 11.205
Authors: Alexandre L A Bentes; Rosivaldo S Borges; Waldinei R Monteiro; Luiz G M de Macedo; Cláudio N Alves Journal: Molecules Date: 2011-02-21 Impact factor: 4.411
Authors: Anna Sampietro; F Javier Pérez-Areales; Paula Martínez; Elsa M Arce; Carles Galdeano; Diego Muñoz-Torrero Journal: Pharmaceuticals (Basel) Date: 2022-04-28
Authors: Tereza Cristina Santos Evangelista; Óscar López; Adrián Puerta; Miguel X Fernandes; Sabrina Baptista Ferreira; José M Padrón; José G Fernández-Bolaños; Magne O Sydnes; Emil Lindbäck Journal: J Enzyme Inhib Med Chem Date: 2022-12 Impact factor: 5.756